Kibow Biotech Inc. (Buzz of Bio Winner, 2014) Receives US Patent for Gout/Hyperuricemia Product Formulation Based on Modulation of the Gut Microbiome With Probiotics and Prebiotics

NEWTOWN SQUARE, Pa., June 20, 2017 /PRNewswire/ -- Kibow Biotech Inc., a pioneer in developing "Enteric Dialysis®" technology, is pleased to announce the issuance of a new patent covering a unique method for preventing or treating gout or hyperuricemia by the U.S. Patent and Trademark Office on May 23^rd 2017. Kibow Biotech Inc., a winner of the Buzz of Bio award in 2014 in San Diego, California, is akin to developing non-drug approaches to chronic disease. Renadyl™, the first and only dietary supplement formulated to maintain healthy kidney function has given healthcare providers and people worldwide hope for maintaining healthy kidney function. Generally probiotic formulations are targeted towards digestive, gut, and immune health. However, Kibow Biotech Inc. is unique in its approach to expand the application of probiotics and prebiotics beyond the aforementioned traditional non-drug applications.

About Gout

Gout is a disease in which uric acid is not removed from the blood, causing arthritis, chalkstones, and episodes of acute pain in the joints and especially smaller bones of the feet. Uric acid is a metabolite product of purines that are found in red meat, beer, and other popular food/drink. At high blood concentrations, uric acid crystallizes and the crystals are deposited in joints, causing the pain and discomfort. In some cases, uric acid crystals can block glomeruli and lead to kidney failure. Over 8.3 million Americans suffer from gout, and the disease is most common in men. A less severe form of gout, known as hyperuricemia is a condition outlining elevated blood uric acid levels, which affects about 21% of the US population (refer to WebMD).  As current treatments for gout carry a wide range of side effects and toxicity, better and safer treatments are needed.

New Patent

The new patent, US 9,655,932 is titled "COMPOSITION AND METHOD FOR PREVENTING OR TREATING GOUT OR HYPERURICEMIA."  This is the 24^th patent issued to Kibow Biotech, Inc. and adds significant value to their already expansive library of intellectual property. Although the gout/hyperuricemia formulation is distinctly different than Renadyl™ (Kibow Biotech's kidney health supplement), the patent covers a composition comprising of a Lactobacillus bacterium, Bifidobacterium  bacterium, and xylo-oligosaccharide to a subject in need of treatment thereby reducing the subject's uric acid levels. Since the product formulation is composed of probiotics and prebiotics with GRAS status (generally recognized as safe) by the FDA, it has potential to be much safer than the products available today. Based on extensive and increased use of probiotics and prebiotics worldwide, the safety of the gout/hyperuricemia formulation will be readily accepted by consumers and healthcare professionals.

About Kibow Biotech Inc.

The Cleveland Clinic has recently announced its list of Top 10 Medical Innovations for 2017 (http://www.cleveland.com/healthfit/index.ssf/2016/10/cleveland_clinic_unveils_its_t.html), the #1 innovation being the utilization of the gut microbiome to prevent, diagnose, and treat disease. Kibow Biotech's flagship product Renadylä is a dietary supplement known for its ability to target and reduce the accumulation of several uremic toxins in the body, thus easing the burden on the kidneys, and maintaining healthy kidney function.  Such a revolutionary mechanism of action has not been widely explored by researchers and nephrologists alike. Kibow Biotech Inc. used similar revolutionary thinking to research and develop this novel approach to treating, or preventing gout or hyperuricemia with the probiotic and prebiotic composition as cited in the patent.

Forward-looking statements:

Renadyl™ is a dietary supplement, and is not intended to treat, cure, prevent, or diagnose disease. The issued gout/hyperuricemia patent covers the intellectual property of developing a pharmaceutical, therapeutic, dietary supplement, etc. for preventing or treating gout or hyperuricemia with a probiotic and prebiotic composition. This press release contains forward-looking statements that reflect management's current views of future events, including the status of development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow Biotech is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ is not intended to cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl™ may not prove to be safe or show evidence of clinical activity in each and every individual due to various environmental or genetic factors. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company, whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Investor & Media Contact:
N. Ranganathan
(610) 353-5130 or [email protected]

SOURCE Kibow Biotech Inc.